Repligen (NASDAQ:RGEN) Releases FY 2025 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.670-1.760 for the period, compared to the consensus earnings per share estimate of 1.710. The company issued revenue guidance of $685.0 million-$710.0 million, compared to the consensus revenue estimate of $692.8 million.

Repligen Trading Up 3.8 %

RGEN opened at $150.73 on Thursday. The business’s 50 day moving average price is $155.04 and its 200 day moving average price is $148.71. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a market capitalization of $8.45 billion, a PE ratio of -407.37, a P/E/G ratio of 4.08 and a beta of 0.99. Repligen has a one year low of $113.50 and a one year high of $207.87.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. HC Wainwright lowered their price target on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Wolfe Research initiated coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. Finally, Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $182.91.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.